A Double-Blind, Placebo-Controlled Phase 2 Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia.
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2012
At a glance
- Drugs Silodosin (Primary)
- Indications Nocturia
- Focus Therapeutic Use
- Sponsors Actavis Inc
- 30 Oct 2009 Actual patient number (215) added as reported by ClinicalTrials.gov.
- 30 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 30 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.